You just read:

Vtesse Secures Additional $17 Million in Series A Extension to Support Further Product Development and Expand the Ongoing Clinical Trial of VTS-270 for the Treatment of Niemann-Pick Type C1 Disease

News provided by

Vtesse, Inc.

Jul 25, 2016, 08:00 ET